

# PeopleIn Limited

## Belt tightening bites

PeopleIn has reported a soft trading update, with 1Q revenues of \$281m (+3% vs. pcp) and EBITDA of \$10m (-33% vs. pcp). The weaker trading conditions are broadly consistent with peer performance in the Asia Pacific region, cycling boom time recruitment conditions from 2021 and 2022. Increased revenue skew to low-margin temporary recruitment categories away from higher-margin permanent recruitment caused major margin contraction during the quarter. We expect the softer year-on-year conditions to prevail during 2Q24e and 3Q24e. FY24e EBITDA and EPS forecasts reduce by -10% and -17% respectively. We see the current year as a cyclical low point, due to the combined effect of lower revenues and operating leverage unwind. PPE has identified cost and efficiency measures to align with the current operating environment. We expect this to support an improved earnings/sales ratio during the latter stages of FY24e. We also note the diversification of PPE's customer segments, with the Food Industry People (FIP) acquisition exhibiting net growth and a likely upswing in the health segment during 2H as an essential service. Net debt/EBITDA is likely to peak above 2x during FY24e, restricting the P/E multiple until earnings momentum turns positive. PPE remains well within debt covenants and recorded 90% cash conversion for Q1. Our DCF-based valuation falls to \$2.09 per share (from \$2.19). We acknowledge that PPE is likely to trade at a discount to fair value until the earnings outlook improves.

### Earnings detractors outweigh support

- We believe that technology, financial services and general industrial segment exposures likely contributed most to the weak 1Q performance.

### First half expectations

- We expect a 1H/2H EBITDA split of \$21.4m/\$23.5m, before adjusting for share based payments.

### \$2.09 price target (from \$2.19), BUY recommendation

- PPE trades on a FY24e EV/EBIT ratio of 7.6x, a 25% discount to the peer average. Next catalyst: 1H results, labour market conditions.

Year-end June (\$)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (\$m)	682.3	1,186.3	1,183.8	1,238.0	1,297.8
EBITDA (\$m)	43.8	55.8	40.4	50.6	53.7
EBIT (\$m)	38.8	47.7	31.2	40.7	43.2
Reported NPAT (\$m)	18.4	20.6	11.8	18.9	20.9
Reported EPS (c)	19.4	20.4	11.5	18.3	20.2
Normalised NPAT (\$m)	25.7	29.0	17.3	24.4	26.4
Normalised EPS (c)	27.0	28.8	16.8	23.6	25.5
EPS Growth (%)	9.4	6.7	(41.6)	39.9	8.1
Dividend (c)	13.0	14.0	10.5	11.5	13.0
Net Yield (%)	8.9	9.6	7.2	7.9	8.9
Franking (%)	100	100	100	100	100
EV/EBITDA (X)	5.2	4.0	5.8	4.7	4.3
Normalised P/E (x)	5.4	5.0	8.6	6.2	5.7
Normalised ROE (%)	20.0	19.2	10.8	14.8	15.2

Source: OML, Iress, PeopleIn Limited

### Last Price

**A\$1.46**

### Target Price

**A\$2.09** (Previously A\$2.19)

### Recommendation

**Buy**


**Risk**

**Higher**

### Human Resource and Employment Services

ASX Code	PPE
52 Week Range (\$)	1.35 - 3.40
Market Cap (\$m)	150.8
Shares Outstanding (m)	103.6
Av Daily Turnover (\$m)	0.4
3 Month Total Return (%)	-33.3
12 Month Total Return (%)	-56.2
Benchmark 12 Month Return (%)	-3.7
NTA FY24E (¢ per share)	-47.6
Net Debt FY24E (\$m)	85.1

### Relative Price Performance



Source: FactSet

### Consensus Earnings

	FY24E	FY25E
NPAT (C) (\$m)	23.1	27.2
NPAT (OM) (\$m)	17.3	24.4
EPS (C) (c)	22.3	25.9
EPS (OM) (c)	16.8	23.6

Source: OML, Iress, PeopleIn Limited

### Ian Munro

Senior Research Analyst  
(03) 9608 4127  
ian.munro@ords.com.au

### Oliver Burston

Research Associate  
(03) 9608 4166  
oburston@ords.com.au

## Key takeaways and outlook

- **A weak first quarter:** PPE has reported 1Q24 revenues of \$281m (+3% vs pcp) and EBITDA of \$10.0m (-33% vs pcp), prior to deducting share-based expenses. The mix of revenues has skewed towards lower margin temporary employment from permanent recruitment. Q1 EBITDA margins reduced to 3.6% (from 5.5%).
- **Revisions to FY24e earnings:** We expect continued year-on-year weakness in the industrial, health and technology/financial service segments during 1H24 and into 2H24e. We note the seasonally stronger June quarter and potential uplift from efficiency measures. FY24e EBITDA forecasts reduces by 10% to \$40.4m (post share-based expenses).
- **Headroom within funding covenants:** PPE's key debt covenant is for gross financial debt/EBITDA < 3x. On our forecasts this ratio is likely to be ~1.7x for FY24e, providing headroom.
- **Regulatory environment reinforces PPE's business model:** Complexity within the Industrial relations environment, including the Pacific Australia Labour Mobility (PALM) scheme, on balance supports PPE's business model, as a key outsourcing partner for major employers in the corporate and Government market in Australia.

Figure 1: Forecast changes

	FY24e			FY25e			FY26e		
	old	new	change %	old	new	change %	old	new	change %
<b>revenue- segments \$m</b>									
Industrial & Specialist	837	879	5%	896	923	3%	954	968	1%
Health & Community*	147	148	1%	153	154	0%	159	160	0%
Professional Services	148	156	6%	153	161	5%	162	170	5%
<b>revenue- total</b>	<b>1133</b>	<b>1184</b>	<b>5%</b>	<b>1203</b>	<b>1238</b>	<b>3%</b>	<b>1276</b>	<b>1298</b>	<b>2%</b>
<b>EBITDA- segments \$m</b>									
Industrial & Specialist	33.3	31.2	-6%	38.4	37.8	-2%	40.7	40.2	-1%
Health & Community*	8.8	8.9	1%	10.4	10.3	0%	10.9	10.8	0%
Professional Services	12.1	9.5	-21%	13.3	12.0	-10%	15.2	12.6	-17%
unallocated	-4.7	-4.7	0%	-5.0	-5.0	0%	-5.4	-5.4	0%
<b>EBITDA - pre SBP "PPE"</b>	<b>49.6</b>	<b>44.9</b>	<b>-9%</b>	<b>57.0</b>	<b>55.1</b>	<b>-3%</b>	<b>61.3</b>	<b>58.2</b>	<b>-5%</b>
share based payments	-4.5	-4.5	0%	-4.5	-4.5	0%	-4.5	-4.5	0%
<b>EBITDA- underlying</b>	<b>45.1</b>	<b>40.4</b>	<b>-10%</b>	<b>52.5</b>	<b>50.6</b>	<b>-4%</b>	<b>56.8</b>	<b>53.7</b>	<b>-6%</b>
EBITDA margin %	4.4%	3.8%	-13%	4.7%	4.4%	-6%	4.8%	4.5%	-7%
<b>Key P&amp;L metrics \$m</b>									
D&A- underlying	-9.2	-9.2	0%	-9.8	-9.8	0%	-10.4	-10.4	0%
EBITA	37.5	32.8	-12%	44.6	42.6	-4%	48.5	45.4	-6%
EBIT	35.9	31.2	-13%	42.7	40.7	-5%	46.4	43.2	-7%
net interest	-6.5	-6.5	0%	-5.7	-5.9	-3%	-5.1	-5.5	-9%
PBT - underlying	29.4	24.7	-16%	37.0	34.9	-6%	41.3	37.7	-9%
NPATA - underlying**	20.6	17.3	-16%	25.9	24.4	-6%	28.9	26.4	-9%
<b>EPS (cents): EPS-A**</b>	<b>20.2</b>	<b>16.8</b>	<b>-17%</b>	<b>25.5</b>	<b>23.6</b>	<b>-8%</b>	<b>28.5</b>	<b>25.5</b>	<b>-10%</b>
D&A - reported	-17.1	-17.1	0%	-17.7	-17.7	0%	-18.3	-18.3	0%
Amortisation - abnormal	-7.8	-7.8	0%	-7.8	-7.8	0%	-7.8	-7.8	0%
Abnormals - pre-tax	0.0	0.0	na	0.0	0.0	na	0.0	0.0	na
reported NPAT	15.1	11.8	-22%	20.4	18.9	-7%	23.4	20.9	-11%
dividend (cents)	10.0	10.5	5%	13.0	11.5	-12%	14.0	13.0	-7%
payout % cash EPS	49%	62%	13%	51%	49%	-2%	49%	51%	2%
<b>Key metrics \$m</b>									
operating cash flow	36.2	30.7	-15%	35.0	34.2	-2%	38.5	36.5	-5%
net capex & leases	-19.2	-19.2	0%	-17.7	-17.7	0%	-18.4	-18.4	0%
acquisitions (incl earn outs)	-12.6	-12.6	0%	-5.5	-5.5	0%	0.0	0.0	na
free cash flow (post tax)	4.5	-1.0	-123%	11.8	11.0	-7%	20.1	18.2	-10%
net debt (cash)	55.0	57.5	5%	53.2	57.1	7%	46.1	50.6	10%
Net debt/EBITDA (with leases)	1.8x	2.1x	15%	1.5x	1.7x	9%	1.3x	1.5x	12%
ROE %	13%	11%	-16%	16%	15%	-5%	16%	15%	-7%
EV/EBITDA x	5.4	5.8	8%	4.6	4.7	1%	4.1	4.3	3%
EV/EBIT x	6.8	7.6	12%	5.7	5.8	2%	5.1	5.3	5%
<b>P/E x</b>	<b>7.8</b>	<b>8.6</b>	<b>11%</b>	<b>6.2</b>	<b>6.2</b>	<b>0%</b>	<b>5.6</b>	<b>5.7</b>	<b>3%</b>

\*\*Ords NPAT and EPS-A excludes only customer contract amortisation and tax adjusts for this.

Source: Ord Minnett Research

## AGM and 1Q24 update

- **Market conditions:** Consistent with global peers, market conditions have softened, with many customers reducing their demand for high-margin roles and delaying decisions, including in health.
- **Implementing efficiency measures:** PPE are driving efficiency measures to realign the cost base in line with the margin shift.
- **Cash collection/conversion above 90%:** Operating cash/EBITDA conversion was above 90% in Q1, a positive outcome.
- **Outlook:** PPE expects the wider downturn to be relatively short-lived, especially within the health segment. The company expect high margin demand to improve in Q4 and into FY25e.
- **Industrial Relations Reform Bill:** A complex bill, likely to be legislated in 2024, that provides an opportunity for PPE as a large and established business, to assist Government and corporate clients navigate the regulatory complexity.
- **PALM Scheme:** The number of workers PPE service on the PALM scheme (via the Food Industry People brand) has increased to 6,000, from 4,700 at the time of acquisition. Approval has been gained to recruit staff into the aged care sector, providing another growth avenue.
- **New CFO:** Adam Leake commenced on 13<sup>th</sup> November 2023 as group CFO.

## Valuation

### \$2.09 valuation (from \$2.19), BUY Recommendation

- We value PPE adopting a DCF methodology with a weighted average cost of capital of 11.6% (from 11.5%), cost of equity of 13.9% (from 13.9%) and terminal growth rate of 3% (no change). The revised DCF valuation is \$2.09 per share (from \$2.19 per share).
- PPE trades on a P/E ratio of 8.6x and an EV/EBIT ratio of 7.6x in FY24e. These represent a 40% and 25% discount to the peer set respectively. PPE is currently trading at a 48% discount versus its 5-year P/E average of 16.7x.

Figure 2: Peer multiples

Company	Mkt cap		Price / Earnings			EV/ EBITDA			EV / Sales		Return on equity		EV / EBIT	
	A\$m	A\$m	FY22	FY23	FY24	FY22	FY23	FY24	FY23	FY24	FY23	FY24	FY23	FY24
APM Group	1,371	2,299	7.9	8.6	8.6	7.6	6.5	5.9	1.2	1.0	9.2	9.7	10.7	9.4
Creek & River Co Ltd	490	394	21.2	17.9	15.1	n.a.	n.a.	7.8	0.9	0.8	19.9	20.1	9.8	8.5
Persol Holdings Co	5,987	5,758	20.2	18.2	16.4	8.4	8.2	7.3	0.5	0.4	16.8	18.7	10.4	10.4
JAC Recruitment	5,987	5,758	20.2	18.2	16.4	8.4	8.2	7.3	0.5	0.4	16.8	18.7	10.4	10.4
WDB Holdings Co	460	264	10.6	13.0	12.0	n.a.	n.a.	n.a.	0.6	0.5	12.4	12.4	5.2	4.9
Hays PLC	3,215	3,318	12.3	13.1	15.2	6.2	6.7	7.7	0.2	0.2	18.9	17.4	8.9	10.6
Page Group	2,840	2,851	10.4	17.1	14.4	5.8	8.2	7.4	0.8	0.8	24.8	29.2	12.2	10.2
Sthree PLC	1,042	958	10.3	10.7	9.9	5.5	5.5	5.0	0.3	0.3	23.2	22.4	7.1	6.4
Robert Walters	599	612	7.9	22.0	11.6	4.2	6.8	4.8	0.3	0.3	8.1	14.8	13.4	7.9
AMN Healthcare Services	3,865	5,336	5.9	8.5	13.2	4.1	6.0	8.6	0.9	1.1	25.9	15.4	9.6	14.8
Kforce Inc	4,080	3,797	8.3	10.2	13.4	4.4	5.1	6.3	0.9	0.9	n.a.	11.0	6.7	8.9
Brunel International NV	930	966	15.6	13.7	11.4	7.5	6.8	6.0	0.4	0.4	13.2	15.0	9.1	7.8
Recruit Holdings	94,818	86,147	30.0	31.2	27.8	17.7	17.3	15.6	2.5	2.5	19.0	18.2	23.3	21.5
Amadeus Fire AG	1,094	1,244	16.7	15.4	13.8	8.1	7.7	7.2	1.7	1.6	24.6	24.2	10.4	9.7
<b>Average</b>			<b>14.1</b>	<b>15.6</b>	<b>14.2</b>	<b>7.3</b>	<b>7.8</b>	<b>7.5</b>	<b>0.8</b>	<b>0.8</b>	<b>17.9</b>	<b>17.7</b>	<b>10.5</b>	<b>10.1</b>
<b>Median</b>			<b>11.5</b>	<b>14.5</b>	<b>13.6</b>	<b>6.8</b>	<b>6.8</b>	<b>7.3</b>	<b>0.7</b>	<b>0.7</b>	<b>18.9</b>	<b>17.8</b>	<b>10.1</b>	<b>9.6</b>
<b>PeopleIn</b>	<b>151</b>	<b>236</b>	<b>5.4</b>	<b>5.0</b>	<b>8.6</b>	<b>5.2</b>	<b>4.0</b>	<b>5.8</b>	<b>0.2</b>	<b>0.2</b>	<b>18.2%</b>	<b>10.8%</b>	<b>4.6</b>	<b>7.6</b>

Source: Ord Minnett Research, Bloomberg

## Industry conditions

Figure 3: International peers, September quarter results

- PPEs International staffing and recruitment competitors experienced negative top line growth across the board during the September quarter as employers continue to slow down the rate of hiring amid ongoing macroeconomic uncertainty. Across APAC / ANZ geographies segment revenue declines ranged between -2% and -24%.

PPE Peers	Sep '23 qtr. group revenue vs. pcp (global)	APAC / ANZ Commentary for the September quarter '23
Hays (UK)	-7.0%	ANZ fee income was down -17% (temp -13% & perm -24%)
Page Group (UK)	-7.9%	Australia total fee income fell -11% vs the pcp.
Robert Walters (UK)	-17.0%	ANZ net fee income was down -24% which was a larger decline than the Group -17%
Robert Half (US)	-14.7%	Non USA revenues (which incl. Australia) fell -7% vs pcp. Group PBT -40% for the quarter vs. pcp
Manpower Group (US)	-5.0%	APAC/Middle East revenue fell -1.6% (currency adjusted), with the segment recording the smallest revenue decline vs other geographies. Group EBIT fell by 57% during the Sep quarter
Randstad (Euro)	-11.0%	Revenue in Australia/New Zealand was down 2% vs the pcp. Group EBITA fell by -19% during the Sep quarter
<b>Median revenue decline</b>	<b>-9.5%</b>	

Source: Ord Minnett Research, Company filings

### Internet job ads

- October saw internet job ads continue to moderate, falling -9.1% vs the pcp to 261,174. Job ads declined -3.8%, or -10,380 month-on-month from September 2023. We note internet job ads remain well above the long-term average of ~188,000.

## Investment thesis

PeopleIn has considerable exposure to the defensive healthcare and fast-growing technology recruitment sectors, which are forecast to grow faster than GDP annually to at least 2026, driven by population growth and demographic changes. PPE's acquisition strategy since listing has taken the brand portfolio to 26 in total whilst still delivering ~10% organic earnings growth since the acquisition. Acquired brands have typically broadened the service offering and geographical spread and added to the stickiness of the group in retaining and expanding panel-based work. PPE's strong return on equity and higher forecast free cash flows suggest the acquisition strategy has delivered positive returns post-integration.

## Overview

PeopleIn is a workforce solutions company providing services to over 4,000 clients across the public and private sectors. PeopleIn operates across three business divisions 1.) Health and Community 2.) Industrial and Specialist Services 3.) Professional Services. Services include sourcing, skilling, deployment, and managing workforce staff across permanent employees and contract hires. Since listing in 2017, PPE has grown its recruitment network to 26 brands that collectively provide payroll for 10,000-15,000 candidates weekly. PeopleIn employs over 850 internal staff and has a national presence.

## Key risks

- **Changing employment conditions:** PPE's core business relies on the ongoing demand for labour. Economic conditions in segments including technology, financial services and industrial services may impact our financial forecasts beyond this earnings revision.
- **Regulatory risk:** PPE's exposure to more unionised and politically sensitive sectors increases the risk of industrial action impacting the company's operations. Changes to government legislation relating to the PALM Scheme may affect the business. However, given the barriers to entry in compliance, panel positions, systems and scale, the more regulated environment may benefit PPE's competitive positioning.
- **Margin outlook:** EBITDA margins for the group declined to 4.8% during the 2H23 (from 5.4% during 1H23). PPE's margins are sensitive to economic conditions and the company's ability to manage cost pressures and utilise staff.

**PeopleIn Limited**

<b>PROFIT &amp; LOSS (A\$m)</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
Revenue	682.3	1,186.3	1,183.8	1,238.0	1,297.8
Operating costs	(638.5)	(1,130.6)	(1,143.4)	(1,187.4)	(1,244.2)
<b>Operating EBITDA</b>	<b>43.8</b>	<b>55.8</b>	<b>40.4</b>	<b>50.6</b>	<b>53.7</b>
D&A	(5.0)	(8.1)	(9.2)	(9.8)	(10.4)
<b>EBIT</b>	<b>38.8</b>	<b>47.7</b>	<b>31.2</b>	<b>40.7</b>	<b>43.2</b>
Net interest	(2.1)	(6.2)	(6.5)	(5.9)	(5.5)
<b>Pre-tax profit</b>	<b>36.7</b>	<b>41.5</b>	<b>24.7</b>	<b>34.9</b>	<b>37.7</b>
Net tax (expense) / benefit	(11.0)	(12.4)	(7.4)	(10.5)	(11.3)
<b>Normalised NPAT</b>	<b>25.7</b>	<b>29.0</b>	<b>17.3</b>	<b>24.4</b>	<b>26.4</b>
<b>Reported NPAT</b>	<b>18.4</b>	<b>20.6</b>	<b>11.8</b>	<b>18.9</b>	<b>20.9</b>
Normalised dil. EPS (cps)	27.0	28.8	16.8	23.6	25.5
Reported EPS (cps)	19.4	20.4	11.5	18.3	20.2
Effective tax rate (%)	28.4	28.4	28.4	28.4	28.4
DPS (cps)	13.0	14.0	10.5	11.5	13.0
Dividend yield (%)	8.9	9.6	7.2	7.9	8.9
Payout ratio (%)	48.1	48.6	62.3	48.8	51.0
Franking (%)	100.0	100.0	100.0	100.0	100.0
Diluted # of shares (m)	101.1	103.6	105.9	105.9	105.9

<b>CASH FLOW (A\$m)</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
EBITDA incl. adjustments	49.9	56.6	40.4	50.6	53.7
Change in working capital	(22.6)	11.2	1.8	(2.4)	(2.6)
Net Interest (paid)/received	(2.1)	(6.2)	(6.5)	(5.9)	(5.5)
Income tax paid	(13.9)	(9.8)	(5.1)	(8.1)	(9.0)
Other operating items	10.8	12.6	-	-	-
<b>Operating Cash Flow</b>	<b>22.0</b>	<b>64.4</b>	<b>30.7</b>	<b>34.2</b>	<b>36.5</b>
Capex	(4.5)	(9.1)	(6.0)	(4.0)	(4.1)
Acquisitions	(50.0)	(12.2)	-	-	-
Other investing items	0.0	-	(12.6)	(5.5)	-
<b>Investing Cash Flow</b>	<b>(54.3)</b>	<b>(21.0)</b>	<b>(18.4)</b>	<b>(9.3)</b>	<b>(3.9)</b>
Inc/(Dec) in borrowings	59.4	(12.9)	(15.0)	(5.0)	(5.0)
Dividends paid	(10.6)	(4.9)	(14.1)	(10.8)	(11.9)
Other financing items	(3.6)	(12.7)	(13.2)	(13.7)	(14.3)
<b>Financing Cash Flow</b>	<b>45.6</b>	<b>(30.5)</b>	<b>(39.3)</b>	<b>(29.5)</b>	<b>(31.2)</b>
Net Inc/(Dec) in Cash	13.2	12.9	(26.9)	(4.6)	1.4

<b>BALANCE SHEET (A\$m)</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
Cash	27.0	39.9	12.9	8.3	9.8
Receivables	115.8	120.3	123.2	128.9	135.1
Inventory	-	-	-	-	-
Other current assets	3.9	3.5	3.5	3.5	3.5
PP & E	15.8	29.8	37.4	45.2	53.3
Investments	-	-	-	-	-
Intangibles	202.0	203.2	210.0	207.6	199.4
Other non-current assets	0.3	0.3	0.3	0.3	0.3
<b>Total Assets</b>	<b>364.8</b>	<b>396.9</b>	<b>387.3</b>	<b>393.8</b>	<b>401.3</b>
Short term debt	32.6	27.9	27.9	27.9	27.9
Payables	51.0	66.6	71.4	74.6	78.2
Other current liabilities	36.6	45.2	45.2	45.2	45.2
Long term debt	65.7	57.5	42.5	37.5	32.5
Other non-current liabilities	36.5	39.6	39.6	39.6	39.6
<b>Total Liabilities</b>	<b>222.4</b>	<b>236.9</b>	<b>226.6</b>	<b>224.9</b>	<b>223.5</b>
<b>Total Equity</b>	<b>142.3</b>	<b>160.0</b>	<b>160.7</b>	<b>168.9</b>	<b>177.8</b>
Net debt (cash)	84.5	73.2	85.1	84.7	78.2

**Buy**

<b>DIVISIONS</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
------------------	--------------	--------------	--------------	--------------	--------------

<b>KEY METRICS (%)</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
Revenue growth	53.5	73.9	(0.2)	4.6	4.8
EBITDA growth	18.7	27.3	(27.6)	25.1	6.1
EBIT growth	14.6	23.0	(34.7)	30.7	6.1
Normalised EPS growth	9.4	6.7	(41.6)	39.9	8.1
EBITDA margin	6.4	4.7	3.4	4.1	4.1
EBIT margin	5.7	4.0	2.6	3.3	3.3
Return on assets	9.5	9.0	5.7	7.5	7.8
Return on equity	20.0	19.2	10.8	14.8	15.2

<b>VALUATION RATIOS (x)</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
Reported P/E	7.5	7.1	12.7	8.0	7.2
Normalised P/E	5.4	5.0	8.6	6.2	5.7
Price To Free Cash Flow	9.9	3.4	13.0	9.1	8.3
Price To NTA	-	-	-	-	-
EV / EBITDA	5.2	4.0	5.8	4.7	4.3
EV / EBIT	5.9	4.6	7.6	5.8	5.3

<b>LEVERAGE</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
ND / (ND + Equity) (%)	37.3	31.4	34.6	33.4	30.6
Net Debt / EBITDA (%)	192.9	131.2	210.5	167.5	145.8
EBIT Interest Cover (x)	18.1	7.6	4.8	7.0	7.8
EBITDA Interest Cover (x)	20.4	8.9	6.2	8.6	9.7

<b>VALUATION</b>	
Cost of Equity (%)	13.9
Cost of debt (after tax) (%)	4.6
D / EV (%)	(25.0)
<b>WACC (%)</b>	<b>11.6</b>
Forecast cash flow (\$m)	82.6
Terminal value (\$m)	144.7
Enterprise Value (\$m)	227.3
<b>Equity NPV Per Share (\$)</b>	<b>2.09</b>

Target Price Method	DCF
Target Price (\$)	2.09
Valuation disc. / (prem.) to share price (%)	43.6

**Institutional Research**

Alastair Hunter	Head of Institutional Research	+61 3 9608 4168	ahunter@ords.com.au
Malcolm Wood	Macro Strategy Analyst	+61 2 8216 6777	mwood@ords.com.au
Lindsay Bettiol	Senior Research Analyst	+61 3 9608 4179	lbettiol@ords.com.au
Nicolas Burgess	Senior Research Analyst	+61 3 9602 9379	nburgess@ords.com.au
James Casey	Senior Research Analyst	+61 3 9602 9265	jamescasey@ords.com.au
Phillip Chippindale	Senior Research Analyst	+61 2 8216 6346	pchippindale@ords.com.au
Tom Godfrey	Senior Research Analyst	+61 7 3214 5587	tgodfrey@ords.com.au
Paul Kaner	Senior Research Analyst	+61 7 3214 5514	pkaner@ords.com.au
Ian Munro	Senior Research Analyst	+61 3 9608 4127	ian.munro@ords.com.au
John O'Shea	Senior Research Analyst	+61 3 9608 4146	joshea@ords.com.au
Leanne Truong	Senior Research Analyst	+61 2 8216 6367	ltruong@ords.com.au
Rushil Paiva	Research Analyst	+61 3 9608 4155	rpaiva@ords.com.au
Tim Elder	Research Associate	+61 7 3214 5565	telder @ords.com.au
Milo Ferris	Research Associate	+61 2 8216 6691	mferris@ords.com.au
Dylan Jones	Research Associate	+61 3 9608 4104	djones@ords.com.au
William Thurlow	Research Associate	+61 2 8216 6623	wthurlow@ords.com.au
Benjamin Yun	Research Associate	+61 2 8216 6646	byun@ords.com.au
Oliver Burston	Research Associate	+61 3 9608 4166	oburston@ords.com.au

**Institutional Sales (Australia)**

Angus Esslemont	Head of Institutional Equities	+61 2 8216 6363	aesslemont@ords.com.au
Jim Bromley	Institutional Equities Sales	+61 2 8216 6343	jbromley@ords.com.au
Stephen Jolly	Institutional Equities Sales	+61 2 8216 6424	sjolly@ords.com.au
Isaac Morris	Institutional Equities Sales	+61 2 8216 6370	imorris@ords.com.au
Scott Ramsay	Institutional Equities Sales	+61 3 9608 4100	sramsay@ords.com.au
Matt White	Institutional Equities Sales	+61 3 9608 4133	mwhite@ords.com.au
Zac Whitehead	Institutional Equities Sales	+61 2 8216 6350	zwhitehead@ords.com.au
Trent Stewart	Institutional Derivatives Sales	+61 2 8216 6622	trent.stewart@ords.com.au
Brendan Sweeney	Operator	+61 2 8216 6781	bsweeney@ords.com.au

**Institutional Sales (Hong Kong)**

Chris Moore	Institutional Equities Sales	+61 2 8216 6362	cmoore@ords.com.hk
-------------	------------------------------	-----------------	--------------------

**Ord Minnett Offices**

**Adelaide**  
Level 5  
100 Pirie Street  
Adelaide SA 5000  
Tel: (08) 8203 2500

**Canberra**  
101 Northbourne Avenue  
Canberra ACT 2600  
Tel: (02) 6206 1700

**Hobart**  
Ground Floor  
85 Macquarie Street  
Hobart TAS 7000  
Tel: (03) 6161 9300

**Melbourne**  
Level 22  
35 Collins Street  
Melbourne VIC 3000  
Tel: (03) 9608 4111

**Head Office  
Sydney**  
Level 18, Grosvenor Place  
225 George Street  
Sydney NSW 2000  
Tel: (02) 8216 6300  
www.ords.com.au

**Brisbane**  
Level 34  
71 Eagle Street  
Brisbane QLD 4000  
Tel: (07) 3214 5555

**Geelong**  
Office 3, Suite 4  
200 Malop Street  
Geelong VIC 3220  
Tel: (03) 4210 0200

**Mackay**  
45 Gordon Street  
Mackay QLD 4740  
Tel: (07) 4969 4888

**Newcastle**  
426 King Street  
Newcastle NSW 2300  
Tel: (02) 4910 2400

**Buderim (Sunshine Coast)**  
1/99 Burnett Street  
Buderim QLD 4556  
Tel: (07) 5430 4444

**Gold Coast**  
Level 7  
50 Appel Street  
Surfers Paradise QLD 4217  
Tel: (07) 5557 3333

**Mildura**  
128 Lime Avenue  
Mildura VIC 3500  
Tel: (03) 9608 4111

**Perth**  
Level 27  
108 St Georges Terrace  
Perth WA 6000  
Tel: (02) 4910 2400

**International  
Hong Kong**  
1801 Ruttonjee House  
11 Duddell Street  
Central, Hong Kong  
Tel: +852 2912 8980  
www.ords.com.hk

**Guide to Ord Minnett Recommendations**

Our recommendations are based on the total return of a stock – nominal dividend yield plus capital appreciation – and have a 12-month time horizon.

<b>SPECULATIVE BUY</b>	We expect the stock’s total return (nominal yield plus capital appreciation) to exceed 20% over 12 months. The investment may have a strong capital appreciation but also has high degree of risk and there is a significant risk of capital loss.
<b>BUY</b>	The stock’s total return (nominal dividend yield plus capital appreciation) is expected to exceed 15% over the next 12 months.
<b>ACCUMULATE</b>	We expect a total return of between 5% and 15%. Investors should consider adding to holdings or taking a position in the stock on share price weakness.
<b>HOLD</b>	We expect the stock to return between 0% and 5%, and believe the stock is fairly priced.
<b>LIGHTEN</b>	We expect the stock’s return to be between 0% and negative 15%. Investors should consider decreasing their holdings.
<b>SELL</b>	We expect the total return to lose 15% or more.
<b>RISK ASSESSMENT</b>	Classified as Lower, Medium or Higher, the risk assessment denotes the relative assessment of an individual stock’s risk based on an appraisal of its disclosed financial information, historical volatility of its share price, nature of its operations and other relevant quantitative and qualitative criteria. Risk is assessed by comparison with other Australian stocks, not across other asset classes such as Cash or Fixed Interest.

**Disclosure:** Ord Minnett is the trading brand of Ord Minnett Limited ABN 86 002 733 048, holder of AFS Licence Number 237121 and is an ASX Group Participant, a Participant of Cboe Australia Pty Ltd and a wholly owned subsidiary of Ord Minnett Holdings Pty Limited ABN 32 062 323 728. Ord Minnett Limited and/or its associated entities, directors and/or its employees may have a material interest in, and may earn brokerage from, any securities referred to in this document. This document is not available for distribution outside Australia, New Zealand and Hong Kong and may not be passed on to any third party or person without the prior written consent of Ord Minnett Limited. Further, Ord Minnett and/or its affiliated companies may have acted as manager or co-manager of a public offering of any such securities in the past three years. Ord Minnett and/or its affiliated companies may provide or may have provided corporate finance to the companies referred to in the report.

Ord Minnett and associated persons (including persons from whom information in this report is sourced) may do business or seek to do business with companies covered in its research reports. As a result, investors should be aware that the firm or other such persons may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

This document is current as at the date of the issue but may be superseded by future publications. You can confirm the currency of this document by checking Ord Minnett’s internet site.

**Disclaimer:** Ord Minnett Limited believes that the information contained in this document has been obtained from sources that are accurate, but has not checked or verified this information. Except to the extent that liability cannot be excluded, Ord Minnett Limited and its associated entities accept no liability for any loss or damage caused by any error in, or omission from, this document. This document is intended to provide general securities advice only, and has been prepared without taking account of your objectives, financial situation or needs, and therefore before acting on advice contained in this document, you should consider its appropriateness having regard to your objectives, financial situation and needs. If any advice in this document relates to the acquisition or possible acquisition of a particular financial product, you should obtain a copy of and consider the Product Disclosure Statement for that product before making any decision. Investments can go up and down. Past performance is not necessarily indicative of future performance.

**Analyst Certification:** The analyst certifies that: (1) all of the views expressed in this research accurately reflect their personal views about any and all of the subject securities or issuers; (2) no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed herein.

**Ord Minnett Hong Kong:** This document is issued in Hong Kong by Ord Minnett Hong Kong Limited, CR Number 1792608, which is licensed by the Securities and Futures Commission (CE number BAI183) for Dealing in Securities (Type 1 Regulated Activity) and Advising on Securities (Type 4 Regulated Activity) and Asset Management (Type 9 Regulated Activity) in Hong Kong. Ord Minnett Hong Kong Limited believes that the information contained in this document has been obtained from sources that are accurate, but has not checked or verified this information. Except to the extent that liability cannot be excluded, Ord Minnett Hong Kong Limited and its associated entities accept no liability for any loss or damage caused by any error in, or omission from, this document. This document is provided for information purposes only and does not constitute an offer to sell (or solicitation of an offer to purchase) the securities mentioned or to participate in any particular trading strategy. The investments described have not been, and will not be, authorized by the Hong Kong Securities and Futures Commission.

For summary information about the qualifications and experience of the Ord Minnett Limited research service, please visit <http://www.ords.com.au/our-team-2/>

For information regarding Ord Minnett Research’s coverage criteria, methodology and spread of ratings, please visit <http://www.ords.com.au/methodology/>

For information regarding any potential conflicts of interest and analyst holdings, please visit <http://www.ords.com.au/methodology/>

The analyst has certified that they were not in receipt of inside information when preparing this report, whether or not it contains company recommendations. Any reports in this publication have been authorised for distribution by Alastair Hunter, Head of Institutional Research at Ord Minnett.